Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019043382 - LEPTIN PEPTIDES AND THEIR USE FOR TREATING NEUROLOGICAL DISORDERS

Publication Number WO/2019/043382
Publication Date 07.03.2019
International Application No. PCT/GB2018/052441
International Filing Date 30.08.2018
IPC
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07K 14/575 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
C07K 7/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
C07K 7/64 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
64Cyclic peptides containing only normal peptide links
A61P 25/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
16Anti-Parkinson drugs
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
16Anti-Parkinson drugs
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/5759
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat
Applicants
  • UNIVERSITY OF DUNDEE [GB]/[GB]
  • UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS [GB]/[GB]
Inventors
  • HARVEY, Jenni
  • DOHERTY, Gayle
Agents
  • Marks & Clerk LLP CHAPMAN, Paul
Priority Data
62/553,05031.08.2017US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) LEPTIN PEPTIDES AND THEIR USE FOR TREATING NEUROLOGICAL DISORDERS
(FR) PEPTIDES DE LEPTINE DÉRIVÉS ET LEUR UTILISATION POUR LE TRAITEMENT DES TROUBLES NEUROLOGIQUES
Abstract
(EN)
A method of treating a neurological disorder comprising administering a leptin peptide fragment comprising amino acids located within the region of amino acids 116 – 125 of leptin is disclosed. The leptin peptide fragment preferably comprises up to 30 amino acids, and/or wherein the leptin peptide fragment comprises one or more amino acids located between amino acids 116 – 122 of leptin, for example the sequence X1CX2LPX3X4 wherein X1 is selected from G or S; X2 is selected from S, H or P; X3 is selected from Q, H, W, L, P or R and X4 is selected from T, A, or V (SEQ ID NO:14) or the sequence SCHLPWASGL (SEQ ID NO:22). The neurological disorder can include those which would benefit from treatment through cognitive enhancement and/or neuroprotection, such as age-associated memory impairment or loss, mild cognitive impairment, and Alzheimer's disease, and can include Parkinson's disease, frontotemporal dementia, progressive supranuclear palsy, Pick's disease, corticobasal degeneration, alcoholic dementia, (DLB) dementia with Lewy bodies, Picks' disease, thalamic dementia, hippocampal sclerosis, Hallervorden-Spatz, multiple system atrophy, tauopathies, subacute aterioscleroitic encephalopathy (Binswanger's disease), amyloid angiopathy, vasculitis, prion diseases, and paraneoplastic syndromes. The invention also includes a pharmaceutical formulation for this method, which can include the peptide in the form of a cyclic peptide or a peptide conjugate.
(FR)
L'invention concerne une méthode de traitement d'un trouble neurologique comprenant l'administration d'un fragment peptidique de leptine comprenant les acides aminés situés dans la région des acides aminés 116–125 de la leptine. Le fragment peptidique de leptine comprend de préférence jusqu'à 30 acides aminés, et/ou le fragment peptidique de leptine comprend un ou plusieurs acides aminés situés entre les acides aminés 116–122 de la leptine, par exemple la séquence X1CX2LPX3X4 où X1 est choisi parmi G ou S ; X2 est choisi parmi S, H ou P ; X3 est choisi parmi Q, H, W, L, P ou R et X4 est choisi parmi T, A, ou V (SEQ ID No : 14) ou la séquence SCHLPWASGL (SEQ ID No : 22). Le trouble neurologique peut comprendre ceux qui pourraient bénéficier du traitement par amélioration cognitive et/ou neuroprotection, tels que la déficience ou la perte de mémoire associée à l'âge, la déficience cognitive légère, et la maladie d'Alzheimer, et peut comprendre la maladie de Parkinson, la démence frontotemporale, la paralysie supranucléaire progressive, la maladie de Pick, la dégénérescence corticobasale, la démence alcoolique, la démence à corps de Lewy (DLB), la démence thalamique, la sclérose hippocampique, le syndrome d'Hallervorden-Spatz, l'atrophie multisystématisée, les tauopathies, l'encéphalopathie subaiguë atériosclérotique (maladie de Binswanger), l'angiopathie amyloïde, la vasculite, les maladies à prions et les syndromes paranéoplasiques. Une formulation pharmaceutique pour ce procédé, qui peut comprendre le peptide sous la forme d'un peptide cyclique ou d'un conjugué peptidique, est en outre décrite.
Also published as
Latest bibliographic data on file with the International Bureau